Market Trends of Global Argatroban Industry
This section covers the major market trends shaping the Argatroban Market according to our research experts:
Heparin-Induced Thrombocytopenia (HIT) is Expected to Dominate the Market Over the Forecast Period
Heparin-induced thrombocytopenia (HIT) is immunemediated and associated with a risk of thrombosis. HIT is an adverse drug reaction caused by the emergence of antibodies that activate platelets in the presence of heparin which is commonly used in hemodialysis. In February 2022, the American Kidney Fund, reported that approximately 570,000 Americans receive dialysis, which shows a significant impact on heparin usage and its adverse drug reaction, Heparin-induced thrombocytopenia (HIT). Thus, demand for argatroban is expected to grow which will drive growth in the argatroban market over the forecast period of the study. Additionally, in December 2020, American Heart Association published that, those patients who received unfractionated heparin for therapeutic and surgical purposes get Heparin-induced thrombocytopenia (HIT) in 0.5% to 1% of cases and patients using low molecular weight heparin (LMWH) have a significantly decreased incidence (0.1% to 0.5%). Thus, demand for argatroban indirectly depends on the type of heparin used in clinical settings, which ultimately impacts the growth of the argatroban market.
The National Audit of Percutaneous Coronary Intervention (PCI) 2021 has published that there was a slight (less than 1%) reduction in total PCI procedures compared with the previous years due to the reduction in the proportion of National Health Service (NHS) centers performing the surgeries during 2019-2020. The use of argatroban in adult patients with or at risk for HIT will increase significantly once the National Health Service (NHS) centers resume their operations of PCI. Thus, demand for argatroban and its market is expected to grow in the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to hold a major market globally due to the development of new formulation products and the increasing prevalence of cardiovascular disorders like stroke, coronary artery disease, and Peripheral arterial disease caused mainly due to the occlusion of blood vessels with thrombosis. In 2022, the Centers for Disease Control and Prevention published that there are approximately 900,000 people affected each year in the United States with thromboembolic events. The major risks for blood clots include older age, obesity, recent surgery or injury, family history of blood clots, cancer treatment, and other lifestyle changes like smoking.
Moreover, peripheral artery disease is a chronic occlusive disease that limits blood flow of the arterial circulation to the lower extremities. Argatroban is the drug used in the treatment of chronic arterial occlusion. So, an increase in the prevalence of peripheral artery disease will have a significant impact on the usage of argatroban. In June 2021, Circulation Research published that the prevalence of peripheral artery disease (PAD) was projected to be 7% in the United States, affecting 8.5 million persons. All these factors and an increase in the prevalence of cardiovascular risk factors, along with the risk of thrombosis in the region are expected to drive the argatroban market over the forecast period.
